Evolution of solid-state NMR in pharmaceutical analysis

Future Medicinal Chemistry

Volumn 2, Issue 6, 2010, Pages 915-921

  Vogt, Frederick G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; CRYSTALLIN;

ACTIVE PHARMACEUTICAL INGREDIENT; CALIBRATION; COST BENEFIT ANALYSIS; CRYSTAL STRUCTURE; DRUG ANALYSIS; DRUG DEVELOPMENT; DRUG FORMULATION; EVOLUTION; FLUORINE NUCLEAR MAGNETIC RESONANCE; IMAGE ENHANCEMENT; MOLECULAR DYNAMICS; NOTE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; SOLID STATE; X RAY POWDER DIFFRACTION;

MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953644733     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.200     Document Type: Note

References (60)

1. Lee SL, Raw AS, Yu L. Significance of drug substance physiochemical properties in regulatory quality by design. In: Drugs and the Pharmaceutical Sciences 178 (Preformulation in Solid Dosage Form Development). Informa Healthcare, NY, USA, 571-583 (2008).
2. Yu L. Pharmaceutical quality by design: product and process development, understanding and control. Pharm. Res. 25(4), 781-791 (2008).
3. Byrn SR, Pfeiffer RR, Stowell JG. Solid-State Chemistry of Drugs. SSCI, West Lafayette, IN, USA (1999).
4. Bernstein J. Polymorphism in Molecular Crystals. Oxford University Press, NY, USA (2002).
5. Harris RK. NMR studies of organic polymorphs and solvates. Analyst 131(3), 351-373 (2006).
6. Kalinowski HO, Berger S, Braun S. Carbon-13 NMR Spectroscopy. Wiley, NY, USA (1988).
7. Berger S, Braun S, Kalinowski HO. NMR Spectroscopy of the Non-Metallic Elements. Wiley, NY, USA (1997).
8. Kaupp M, Bühl M, Malkin VG. Calculation of NMR and EPR Parameters. Wiley-VCH, Weinheim, Germany (2004).
9. Orendt AM, Facelli JC. Solid state effects on NMR chemical shifts. Ann. Rep. NMR Spectr. 62, 115-178 (2007).
10. Carss SA, Harris RK, Fletton RA. Carbon-13 NMR investigations of three fluorinated steroids. Magn. Reson. Chem. 33(7), 501-505 (1995).
11. Reutzel-Edens SM, Bush JK, Magee PA, Stephenson GA, Byrn SR. Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships. Cryst. Growth Des. 3(6), 897-907 (2003).
12. Apperley DC, Fletton RA, Harris RK, Lancaster RW, Tavener S, Threlfall TL, Sulfathiazole polymorphism studied by magic-angle spinning NMR. J. Pharm. Sci. 88(12), 1275-1280 (1999).
13. Wenslow RM, Baum MW, Ball RG, McCauley JA, Varsolona RJ. A spectroscopic and crystallographic study of polymorphism in an aza-steroid. J. Pharm. Sci. 89(10), 1271-1285 (2000).
14. Zell MT, Padden BE, Grant DJW, Schroeder SA, Wachholder KL, Prakash I, Munson EJ. Investigation of polymorphism in aspartame and neotame using solid-state NMR spectroscopy. Tetrahedron 56(36), 6603-6616 (2000).
15. Portieri A, Harris RK, Fletton RA, Lancaster RW, Threlfall TL. Effects of polymorphic differences for sulfanilamide, as seen through 13C and 15N solid-state NMR, together with shielding calculations. Magn. Reson. Chem. 42(3), 313-320 (2004).
16. Vogt FG, Cohen DE, Bowman JD et al. Structural analysis of polymorphism and solvation in tranilast. J. Pharm. Sci. 94(3), 651-665 (2005).
17. Sheth AR, Lubach JW, Munson EJ, Muller FX, Grant DJW. Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes. J. Am. Chem. Soc. 127(18), 6641-6651 (2005).
18. Li ZJ, Abramov Y, Bordner J, Leonard J, Medek A, Trask AV. Solid-state acid-base interactions in complexes of heterocyclic bases with dicarboxylic acids: crystallography, hydrogen bond analysis, and 15N NMR spectroscopy. J. Am. Chem. Soc. 128(25), 8199-8210 (2006).
19. Vogt FG, Clawson JS, Strohmeier M, Pham TN, Watson SA, Edwards AJ. New approaches to the characterization of drug candidates by solid-state NMR. In: The Handbook of Pharmaceutical Formulations Wiley, NY, USA (2010) (In Press).
20. Offerdahl TJ, Salsbury JS, Dong Z et al. Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy. J. Pharm. Sci. 94(12), 2591-2605 (2005).
21. Böhm HJ, Banner D, Bendels S et al. Fluorine in medicinal chemistry. ChemBioChem 5(5), 637-643 (2004).
22. Müller K, Faeh C, Diederich F. Flourine in pharmaceuticals: looking beyond intuition. Science 317(5846), 1881-1886 (2007).
23. Stringer JA, Drobny GP. Methods for the analysis and design of a solid-state nuclear magnetic resonance probe. J. Chem. Phys. 69(9), 3384-3391 (1998).
24. Wenslow RM. 19F solid-state NMR spectroscopic investigation of crystalline and amorphous forms of a selective muscarinic M3 receptor antagonist, in both bulk and pharmaceutical dosage form samples. Drug Dev. Ind. Pharm. 28(5), 555-561 (2002).
25. Farrer BT, Peresypkin A, Wenslow RM. Quantitation of crystalline material within a liquid vehicle using 1H/19F CP/MAS NMR. J. Pharm. Sci. 96(2), 264-267 (2007).
26. Katrincic LM, Sun YT, Carlton RA, Diederich AM, Mueller RL, Vogt FG. Characterization, selection, and development of an orally-dosed drug polymorph from an enantiotropically-related system. Int. J. Pharm. 366(1-2), 1-13 (2009).
27. Lubach JW, Xu D, Segmuller BE, Munson EJ. Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability. J. Pharm. Sci. 96(4), 777-787 (2007).
28. Geppi M, Mollica G, Borsacchi S, Veracini CA. Solid-state NMR studies of pharmaceutical systems. Appl. Spectros. Rev. 43(3), 202-302 (2008).
29. Harris RK, Hodgkinson P, Larsson T, Muruganantham A. Quantification of bambuterol hydrochloride in a formulated product using solid-state NMR. J. Pharm. Biomed. Anal. 38(5), 858-864 (2005).
30. Mollica G, Geppi M, Pignatello R, Veracini CA. Molecular properties of flurbiprofen and its solid dispersions with Eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance. Pharm. Res. 23(9), 2129-2140 (2006).
31. Reutzel-Edens SM, Bush JK. Solid-state NMR spectroscopy of small molecules: from NMR crystallography to the characterization of solid oral dosage forms. Am. Pharm. Rev. 5(2), 112-115 (2002).
32. Vogt FG. A multi-disciplinary approach to the solid-state analysis of pharmaceuticals. Am. Pharm. Rev. 11(5), 50-57 (2008).
33. Vogt FG, Nuclear magnetic resonance. In: Ewing's Analytical Instrumentation Handbook (Third Edition). Cazes J (Ed.). Marcel Dekker, NY, USA, 295-348 (2004).
34. van Rossum BJ, Förster H, de Groot HJM. High-field and high-speed CP-MAS 13C NMR heteronuclear dipolar-correlation spectroscopy of solids with frequency-switched Lee-Goldburg homonuclear decoupling. J. Magn. Reson. 124, 516-519. (1997).
35. Vogt FG, Brum J, Katrincic LM et al. Physical, crystallographic, and spectroscopic characterization of a crystalline pharmaceutical hydrate: understanding the role of water. Cryst. Growth Des. 6(1), 2333-2354 (2006).
36. Zhou DH, Rienstra CM. Rapid analysis of organic compounds by proton-detected heteronuclear correlation NMR spectroscopy with 40 kHz magic-angle spinning. Angew. Chem. Int. Ed. 47(38), 7328-7331 (2008).
37. Griffin JM, Martin DR, Brown SP. Distinguishing anhydrous and hydrous forms of an active pharmaceutical ingredient in a tablet formulation using solid-state NMR spectroscopy. Angew. Chem. Int. Ed. 46, 8036-8038 (2007).
38. Elena B, Emsley L. Powder crystallography by proton solid-state NMR. J. Am. Chem. Soc. 127(25), 9140-9146 (2005).
39. Elena B, Pintacuda G, Mifsud N, Emsley L. Molecular structure determination in powders by NMR crystallography from proton spin diffusion. J. Am. Chem. Soc. 128(29), 9555-9560 (2006).
40. Pickard CJ, Salager E, Pintacuda G, Elena B, Emsley L. Resolving structures from powders by NMR crystallography using combined proton spin diffusion and plane wave DFT calculations. J. Am. Chem. Soc. 129(29), 8932-8933 (2007).
41. Vogt FG, Katrincic LM, Long ST et al. Enantiotropically-related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4- (methyloxy)phenyl]-1,3-thiazol- 5-yl} acetic acid. Crystal structures and multinuclear solid-state NMR. J. Pharm. Sci. 97(11), 4756-4782 (2008).
42. Salager E, Stein RS, Pickard CJ, Elena B, Emsley L. Powder NMR crystallography of thymol. Phys. Chem. Chem. Phys. 11(15), 2610-2621 (2009).
43. Riekel C, Burghammer M, Schertler G. Protein crystallography microdiffraction. Cur. Opin. Struct. Biol. 15(5), 556-562 (2005).
44. Vogt FG, Clawson JS, Strohmeier M, Edwards AJ, Pham TN, Watson SA. Solid-state NMR analysis of organic cocrystals and complexes. Cryst. Growth Des. 9(2), 921-937 (2009).
45. Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals - an opportunity for drug product enhancement. Exp. Opin. Drug Delivery 6(4), 333-341 (2009).
46. Clawson JS, Vogt FG, Brum J et al. Formation and characterization of crystals containing a pleuromutilin derivative, succinic acid and water. Cryst. Growth Des. 8(11), 4120-4131 (2008).
47. Vogt FG, Vena JA, Chavda M, Clawson JS, Strohmeier M, Barnett ME. Structural analysis of 5-fluorouracil and thymine solid solutions. J. Mol. Struct. 932(1-3), 16-30 (2009).
48. Vogt FG, Copley RCB, Mueller RL et al. Isomorphism, disorder and hydration in the crystal structures of racemic and single-enantiomer carvedilol phosphate. Cryst. Growth Des. In press (2010).
49. Hamaed H, Pawlowski JM, Cooper BFT, Fu RQ, Eichhorn SH, Schurko RW. Application of solid-state 35Cl NMR to structural characterization of hydrochloride pharmaceuticals and their polymorphs. J. Am. Chem. Soc. 130(33), 11056-11065 (2008).
50. Lipton AS, Heck RW, de Jong WA et al. Low temperature 65Cu NMR spectroscopy of the Cu+ site in azurin, J. Am. Chem. Soc. 131(39), 13992-13999 (2009).
51. Vogt FG, Dell'Orco PC, Diederich AM et al. A study of variable hydration states in topotecan hydrochloride. J. Pharm. Biomed. Anal. 40(5), 1080-1088 (2006).
52. Heise H. Solid-state NMR spectroscopy of amyloid proteins, ChemBioChem 9(2), 179-189 (2008).
53. Middleton DA. NMR methods for characterising ligand-receptor and drug-membrane interactions in pharmaceutical research. Ann. Rep. NMR Spectros. 60, 39-75 (2006).
54. Baldus M. Molecular interactions investigated by multi-dimensional solid-state NMR. Curr. Opin. Struct. Biol. 16(5), 618-623 (2006). (Pubitemid 44466405)
55. Williamson PTF. Solid-state NMR for the analysis of high-affinity ligand/receptor interactions. Concepts Magn. Reson. 34A(3), 144-172 (2009).
56. Chen L, Kaiser JM, Polenova T, Yang J, Rienstra CM, Mueller LJ. Backbone assignments in solid-state proteins using J-based 3D heteronuclear correlation spectroscopy. J. Am. Chem. Soc. 129(35), 10650-10651 (2007).
57. Gan Z, Amoureux JP, Trebosc J. Proton-detected 14N MAS NMR using homonuclear decoupled rotary resonance. Chem. Phys. Lett. 435(1-3), 163-169 (2007).
58. O'Dell LA, Schurko RW. Fast and simple acquisition of solid-state 14N NMR spectra with signal enhancement via population transfer. J. Am. Chem. Soc. 131(19), 6658-6659 (2009).
59. Io T, Fukami T, Yamamoto K et al. Homogeneous nanoparticles to enhance the efficiency of a hydrophobic drug, antihyperlipidemic probucol, characterized by solid-state NMR. Mol. Pharm. 7(1), 299-305 (2010).
60. Pikal MJ, Rigsbee D, Roy ML et al. Storage stability of freeze-dried human growth hormone (hGH) with structure and dynamics in the glassy solid. J. Pharm. Sci. 97, 5106-5121 (2008).